Cellestial Health
Cellestial Health is an early-stage preclinical biopharmaceutical Cambridge spin-out developing therapies protecting astrocytic networks for Parkinson's and other brain disorders.
- Company
- Cambridge, GBUnited Kingdom
Cellestial Health is an early-stage preclinical biopharmaceutical Cambridge spin-out developing therapies protecting astrocytic networks for Parkinson's and other brain disorders.
cellestialhealth.comCrawled Nov 3, 2026
about Learn About Parkinson's Disease Disclaimer: This website is intended for informational purposes only and is not for commercial use. Cellestial Health is committed to providing access to educational materials and as such, may offer links to third-party sites to help you explore more about the condition.We are not soliciting patient inquiries regarding accessing our…
At Cellestial Health we are pioneering a groundbreaking approach to brain health by targeting astrocytes, the vital brain cells that regulate multiple brain functions including movement, memory, and sleep, but have been overlooked by existing therapies. While traditional therapies focus primarily on brain cells called neurons, novel research, including our study conducted at the University of Cambridge, reveals that…
Are all astrocytes the same in Parkinson's? Astrocytes represent a brain cell type that is found across all areas of the brain. Depending on the region, they comprise 1/3rd - 2/3rds of all cells, and network coupling is an important feature of all astrocytes. However, multiple differences have been noted among astrocytic populations, both within…
Cambridge Academy of Therapeutic Sciences features the story of the founder of Cellestial Health, Dr Nat Hastings, as a translational researcher at the University of Cambridge in the latest Accelerating Translation report. This work formed valuable background IP which supported the spin-off of Cellestial. Celebrate our and our colleagues' successes and find out which challenges…
Cells can't do it alone, and Cellestial Health team members Dr Nat Hastings and Dr Saifur Rahman couldn't have done it alone either. This is why they tapped into their Cambridge network and attended a week packed of lectures and events at the Judge Business School as part of the summer 2024 "Ignite" program. Learn…
Cellestial Health is a spin-out from the University of Cambridge, but did you know that we have academic collaborations across the UK and globally - including with the University of Manchester. Our connection with Manchester started in the summer 2024 at the Innovation Lab event which welcomed four industry partners to team up with the…
Cellestial team are grateful for the nomination for the prestigious #21toWatch Award showcasing leaders across Cambridge and the East of England - we have made it to the Companies longlist. We are looking forward to seeing all the amazing people, companies, and things showcased by the campaign. Find out more: https://www.21towatch.com
Friends, Cellestial Health is honoured to be shortlisted in the prestigious #21toWatch Companies list - among other impressive contestants such as Lucy Jung, co-founder of Charco Neurotech, and Jonathan Fisher. Both of these inventors are working on wearable devices to reduce motor symptoms of Parkinson's. At the same time, Arko Paul at Oltera is designing…
Welcome to our Investment & Funding page, here you will find the summary focussed on the latest open funding round, closed rounds, and grant funding secured. Subscribe for quarterly updates
Welcome to our press and media reel, here you will find the latest company updates, announcements and research materials. Subscribe for quarterly updates
At Cellestial Health, strategic partnerships and collaborations are key to driving our mission forward. By working with leading institutions and leveraging diverse funding sources, we accelerate the development of innovative therapies for Parkinson’s. Our collaborative approach enables us to advance cutting-edge research, strengthen our discovery pipeline, and pave the way for the next generation of…
At the heart of Cellestial Health is a constellation of brilliant minds: our dedicated core team, world-class scientific advisory board, and visionary funders, all working in harmony to propel our mission forward.Each quarter, we convene with our board and investors to share updates on the preclinical progress of our lead candidate, keeping them aligned with…
The Competitive Market: Our 10 Cellestial Steps These are the 10 steps that define Cellestial Health's place in the market. We've outlined these steps to provide a clear roadmap for how we differentiate ourselves, from pioneering science to strategic positioning. Each step reflects our commitment to advancing Parkinson’s treatment and solidifying our leadership in this…
Paradigm Shift for Parkinson's At Cellestial Health, our mission is to pioneer disruptive yet accessible therapies that restore and protect astrocytic networks, addressing incurable conditions such as Parkinson’s Disease. We are committed to reducing the global burden of neurodegenerative diseases, promoting health equity, and advancing science with the potential to transform lives. The Four Cellestial…
Contact us We welcome collaboration requests and enquiries from organisations, researchers, and investors who share our values and goals to advance treatments for brain diseases. If you're interested in learning more about our work or exploring partnership opportunities, please get in touch with our Cellestial Health team.Complete the contact form to start the conversation. Polite…
From our constellation to yours, a quarterly update delivered straight to your mailbox. Our Cellestograms are carefully curated to share the news, ideas, and breakthroughs shaping Cellestial Health. They offer a glimpse into the science, partnerships, and events driving our mission to improve brain health. Expect an update at the end of each quarter. Each…
Protecting brain networks to stop brain disease.
Researchers at the University of Cambridge and its spinout **Cellestial Health**, alongside the University of Manchester, identify a potential new therapy targeting overlooked brain cell networks to slow Parkinson’s disease progression. The study, published in *Experimental Neurology*, proposes an experimental approach that could alter disease development. Findings highlight previously understudied neural pathways as key intervention points.
Jul 2026Cambridge NeuroscienceNews article
Cellestial Health secures backing from ET Capital’s Cambridge Venture Index Fund (CVIF), which invests in deep science companies from Cambridge and Oxford. The biopharmaceutical firm develops novel Parkinson’s disease drugs targeting a patient population exceeding 10 million globally. ET Capital highlights the fund’s track record of outperforming the FTSE 100 since 2005 through Cambridge-based spinouts.
Apr 2026Cellestial HealthNews article
Parkinson’s UK awards **Cellestial Health** £55,000 to investigate brain cell networks as potential targets for novel Parkinson’s treatments. The funding supports ongoing research into mechanisms that could inform future therapeutic strategies. The organization focuses on mapping neural pathways linked to disease progression.
Sep 2025Parkinson's UKNews article
Cellestial Health raises pre-seed funding amid rising investor scrutiny toward early-stage biotech firms. The company operates in a market where Most Favoured Nation (MFN) drug pricing policies introduce revenue uncertainty. Investors now weigh risks more carefully due to these evolving financial conditions.
May 2025bioindustry.orgNews article